OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Comparative Immunomodulatory Evaluation of the Receptor Binding Domain of the SARS-CoV-2 Spike Protein; a Potential Vaccine Candidate Which Imparts Potent Humoral and Th1 Type Immune Response in a Mouse Model
Tripti Shrivastava, Balwant Singh, Zaigham Abbas Rizvi, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Tripti Shrivastava, Balwant Singh, Zaigham Abbas Rizvi, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25
Showing 25 citing articles:
Advances in the design and development of SARS-CoV-2 vaccines
Xue‐Liang Peng, Ji‐Si‐Yu Cheng, Hai‐Lun Gong, et al.
Military Medical Research (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 66
Xue‐Liang Peng, Ji‐Si‐Yu Cheng, Hai‐Lun Gong, et al.
Military Medical Research (2021) Vol. 8, Iss. 1
Open Access | Times Cited: 66
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad R. Medigeshi, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 4, pp. 473-482
Open Access | Times Cited: 61
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad R. Medigeshi, et al.
The Lancet Infectious Diseases (2021) Vol. 22, Iss. 4, pp. 473-482
Open Access | Times Cited: 61
Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
Rajesh Vikkurthi, Asgar Ansari, Anupama Ramakanth Pai, et al.
Nature Microbiology (2022) Vol. 7, Iss. 7, pp. 974-985
Open Access | Times Cited: 49
Rajesh Vikkurthi, Asgar Ansari, Anupama Ramakanth Pai, et al.
Nature Microbiology (2022) Vol. 7, Iss. 7, pp. 974-985
Open Access | Times Cited: 49
Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 16
Xiao‐Qing Guan, Yang Yang, Lanying Du
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 422-439
Open Access | Times Cited: 16
Oral Immunisation With Non‐GMO Surface Displayed SARS ‐CoV ‐2 Spike Epitopes on Bacteria‐Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice
Robie Vasquez, Ji Hoon Song, Remilyn M. Mendoza, et al.
Microbial Biotechnology (2025) Vol. 18, Iss. 1
Open Access
Robie Vasquez, Ji Hoon Song, Remilyn M. Mendoza, et al.
Microbial Biotechnology (2025) Vol. 18, Iss. 1
Open Access
CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters
Jyotsna Dandotiya, Neeta Adhikari, Manas Ranjan Tripathy, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Jyotsna Dandotiya, Neeta Adhikari, Manas Ranjan Tripathy, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Antigenic epitope screening and functional modification of mannose enhance the efficacy of largemouth bass virus subunit vaccines
Yijun Jia, Jun‐Yao Xia, Fu‐Yi Jiang, et al.
Journal of Fish Diseases (2022) Vol. 45, Iss. 11, pp. 1635-1643
Closed Access | Times Cited: 18
Yijun Jia, Jun‐Yao Xia, Fu‐Yi Jiang, et al.
Journal of Fish Diseases (2022) Vol. 45, Iss. 11, pp. 1635-1643
Closed Access | Times Cited: 18
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 17
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants
Sakshi Bajoria, Kawaljit Kaur, Ozan S. Kumru, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 17
Sakshi Bajoria, Kawaljit Kaur, Ozan S. Kumru, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 17
Non-neutralizing SARS CoV-2 directed polyclonal antibodies demonstrate cross-reactivity with the HA glycans of influenza virus
Praveenkumar Murugavelu, Reshma Perween, Tripti Shrivastava, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108020-108020
Open Access | Times Cited: 17
Praveenkumar Murugavelu, Reshma Perween, Tripti Shrivastava, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108020-108020
Open Access | Times Cited: 17
Designed SARS‐CoV‐2 receptor binding domain variants form stable monomers
Miriam Klausberger, Nikolaus F. Kienzl, Gerhard Stadlmayr, et al.
Biotechnology Journal (2022) Vol. 17, Iss. 5
Open Access | Times Cited: 11
Miriam Klausberger, Nikolaus F. Kienzl, Gerhard Stadlmayr, et al.
Biotechnology Journal (2022) Vol. 17, Iss. 5
Open Access | Times Cited: 11
Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli
Intan Aghniya Safitri, Yovin Sugijo, Fernita Puspasari, et al.
Vaccine X (2024) Vol. 16, pp. 100443-100443
Open Access | Times Cited: 1
Intan Aghniya Safitri, Yovin Sugijo, Fernita Puspasari, et al.
Vaccine X (2024) Vol. 16, pp. 100443-100443
Open Access | Times Cited: 1
Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models
Ricardo Choque-Guevara, Astrid Poma-Acevedo, Ricardo Montesinos, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0269823-e0269823
Open Access | Times Cited: 7
Ricardo Choque-Guevara, Astrid Poma-Acevedo, Ricardo Montesinos, et al.
PLoS ONE (2022) Vol. 17, Iss. 8, pp. e0269823-e0269823
Open Access | Times Cited: 7
Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 B·1·617·2 Delta Variant Despite Reduced Virus Neutralisation
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad R. Medigeshi, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 9
Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad R. Medigeshi, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 9
The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41
Reshma Perween, Praveenkumar Murugavelu, Tripti Shrivastava, et al.
International Immunopharmacology (2021) Vol. 101, pp. 108187-108187
Open Access | Times Cited: 9
Reshma Perween, Praveenkumar Murugavelu, Tripti Shrivastava, et al.
International Immunopharmacology (2021) Vol. 101, pp. 108187-108187
Open Access | Times Cited: 9
Inactivated virus vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern
Rajesh Vikkurthi, Asgar Ansari, Anupama Ramakanth Pai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 9
Rajesh Vikkurthi, Asgar Ansari, Anupama Ramakanth Pai, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 9
Pre-Clinical Safety and Immunogenicity Study of a Coronavirus Protein-Based Subunit Vaccine for COVID-19
Kamshat Shorayeva, Aziz Nakhanov, Ainur Nurpeisova, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1771-1771
Open Access | Times Cited: 2
Kamshat Shorayeva, Aziz Nakhanov, Ainur Nurpeisova, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1771-1771
Open Access | Times Cited: 2
Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells
Chandra Shekhar Kumar, Balwant Singh, Zaigham Abbas Rizvi, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 10, pp. 2119-2132
Closed Access | Times Cited: 4
Chandra Shekhar Kumar, Balwant Singh, Zaigham Abbas Rizvi, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 10, pp. 2119-2132
Closed Access | Times Cited: 4
Trichinella spiralis Infection Inhibits the Efficacy of RBD Protein of SARS-CoV-2 Vaccination via Regulating Humoral and Cellular Immunity
Fei-Fan Zhu, Wenwen Zheng, Yiyan Gong, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 729-729
Open Access
Fei-Fan Zhu, Wenwen Zheng, Yiyan Gong, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 729-729
Open Access
Identification and Ranking of Binding Sites from Structural Ensembles: Application to SARS-CoV-2
Maria Lazou, Ayse A. Bekar-Cesaretli, Sándor Vajda, et al.
Viruses (2024) Vol. 16, Iss. 11, pp. 1647-1647
Open Access
Maria Lazou, Ayse A. Bekar-Cesaretli, Sándor Vajda, et al.
Viruses (2024) Vol. 16, Iss. 11, pp. 1647-1647
Open Access
Designing a Vaccine Platform composed of Phage encapsulated with Chitosan Nanoparticles Targeting Pathogenic Viruses
Faten Mohammed Mahdi Shukur
JOURNAL OF COMMUNICABLE DISEASES (2023) Vol. 55, Iss. 02, pp. 9-17
Open Access | Times Cited: 1
Faten Mohammed Mahdi Shukur
JOURNAL OF COMMUNICABLE DISEASES (2023) Vol. 55, Iss. 02, pp. 9-17
Open Access | Times Cited: 1
Potential mouse models of coronavirus-related immune injury
Fu-Yao Nan, Caijun Wu, Jia-Hui Su, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 2
Fu-Yao Nan, Caijun Wu, Jia-Hui Su, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 2
A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Lorena M. Coria, Lucas M. Saposnik, Celeste Pueblas Castro, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 2
Dietary αKG inhibits SARS CoV-2 infection and rescues inflamed lungs to restore normal O2saturation in animals
Sakshi Agarwal, Simrandeep Kaur, Tejeswara Rao Asuru, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Sakshi Agarwal, Simrandeep Kaur, Tejeswara Rao Asuru, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models
Ricardo Choque-Guevara, Astrid Poma-Acevedo, Ricardo Montesinos, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 1
Ricardo Choque-Guevara, Astrid Poma-Acevedo, Ricardo Montesinos, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 1
